Kane Biotech Inc.
KNBIF
$0.03
$0.0024.38%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 42.30K | 298.60K | 403.70K | 1.34M | 1.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.30K | 298.60K | 403.70K | 1.34M | 1.77M |
| Cost of Revenue | 76.30K | 300.30K | 473.10K | 994.00K | 1.13M |
| Gross Profit | -34.00K | -1.60K | -69.30K | 344.10K | 640.50K |
| SG&A Expenses | 1.08M | 1.41M | 1.27M | 1.71M | 2.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.57M | 2.15M | 2.39M | 3.38M | 4.42M |
| Operating Income | -1.53M | -1.85M | -1.99M | -2.04M | -2.65M |
| Income Before Tax | -1.67M | -2.01M | -2.32M | -2.37M | -3.01M |
| Income Tax Expenses | -74.50K | -77.50K | -936.00K | -936.00K | -936.00K |
| Earnings from Continuing Operations | -1.60 | -1.93 | -1.38 | -1.44 | -2.07 |
| Earnings from Discontinued Operations | -- | -- | -936.00K | -882.60K | 6.73M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.60M | -1.93M | -2.32M | -2.32M | 4.66M |
| EBIT | -1.53M | -1.85M | -1.99M | -2.04M | -2.65M |
| EBITDA | -1.40M | -1.71M | -1.82M | -1.91M | -2.52M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | 0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | 0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 865.64M | 833.84M | 757.01M | 561.47M | 530.80M |
| Average Diluted Shares Outstanding | 883.13M | 851.33M | 774.50M | 578.96M | 556.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |